A wide variety of new therapeutic options for Multiple Myeloma (MM) have recently become
available, extending progression-free and overall survival for patients in meaningful ways …

Use of surrogate end‐points such as progression‐free survival (PFS) and other time‐to‐
event (TTE) end‐points is common in multiple myeloma (MM) clinical trials. This systematic …

Despite recent advances, multiple myeloma remains an incurable disease for most patients,
and initial remission will be followed by relapses requiring therapy. For many, there will be …

The oral BCL‐2 inhibitor venetoclax has demonstrated promising efficacy in patients with t
(11; 14) plasma cell disorders, both as a single‐agent and in combination. However, there …

Almost all patients with multiple myeloma (MM) eventually relapse, either asymptomatically
or with end-organ damage. However, it remains unclear whether initiating therapy at the …

Objectives: There may be a shift in risk stratification at progression compared to that at
diagnosis in patients with multiple myeloma (MM). We aimed to evaluate whether re-staging …

Background The anti-CD38 monoclonal antibody daratumumab is approved as a single
agent for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) who …

Abstract Purpose of Review With rapid advances in the therapeutic landscape and
biological insights in multiple myeloma, it is critical to identify and strategically manage high …

Multiple myeloma (MM) is a prevalent hematological malignancy. Resource-constrained
settings such as the Middle East are particularly burdened by the increasing trends in MM …

Objective: Patients with triple-class refractory (TCR) multiple myeloma (MM) have limited
treatment options and poor prognoses. This high unmet need has prompted the …